What question did this study set out to answer?

This report summarizes investigational epilepsy treatments presented at the EILAT XVIII conference, focusing on their potential benefits.

July 20, 2026Epilepsia

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVIII ). II . Treatments in more advanced clinical development

View Full Paper

Ask AI

Bookmark

Authors

Progress report reveals new promising epilepsy treatments in advanced clinical development, suggesting better outcomes for patients.

This report summarizes investigational epilepsy treatments presented at the EILAT XVIII conference, focusing on their potential benefits.
Data compilation from 13 investigational treatments reported at the conference.
Review of treatment mechanisms and targeted epilepsy types.
Evaluation of preliminary seizure outcomes for each treatment.
Bexicaserin and BMB-101 show promise in treating developmental and epileptic encephalopathies.
ETX-101, a gene therapy, targets SCN1A-positive Dravet syndrome with potential positive outcomes.
Overall, the treatments reviewed indicate improved outcomes for patients resistant to current therapies.

Bialer et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark